ATE501259T1 - Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen - Google Patents

Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Info

Publication number
ATE501259T1
ATE501259T1 AT98926055T AT98926055T ATE501259T1 AT E501259 T1 ATE501259 T1 AT E501259T1 AT 98926055 T AT98926055 T AT 98926055T AT 98926055 T AT98926055 T AT 98926055T AT E501259 T1 ATE501259 T1 AT E501259T1
Authority
AT
Austria
Prior art keywords
piv
production
recombinant
attenuate
nucleotide sequences
Prior art date
Application number
AT98926055T
Other languages
English (en)
Inventor
Brian Murphy
Peter Collins
Anna Durbin
Mario Skiadopoulos
Tao Tao
Original Assignee
Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services filed Critical Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services
Application granted granted Critical
Publication of ATE501259T1 publication Critical patent/ATE501259T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT98926055T 1997-05-23 1998-05-22 Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen ATE501259T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4757597P 1997-05-23 1997-05-23
US5938597P 1997-09-19 1997-09-19
PCT/US1998/010551 WO1998053078A1 (en) 1997-05-23 1998-05-22 Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences

Publications (1)

Publication Number Publication Date
ATE501259T1 true ATE501259T1 (de) 2011-03-15

Family

ID=26725195

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98926055T ATE501259T1 (de) 1997-05-23 1998-05-22 Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Country Status (10)

Country Link
EP (1) EP0994949B1 (de)
JP (2) JP4237268B2 (de)
KR (1) KR100702523B1 (de)
CN (1) CN1250725C (de)
AT (1) ATE501259T1 (de)
AU (1) AU7797798A (de)
BR (1) BR9809456B1 (de)
CA (1) CA2291216A1 (de)
DE (1) DE69842165D1 (de)
WO (1) WO1998053078A1 (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465574B2 (en) 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
ATE451451T1 (de) 1996-07-15 2009-12-15 Us Gov Health & Human Serv Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US6830748B1 (en) 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
EP1098961B1 (de) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon induzierende genetisch veränderte attenuierte viren
DK2316923T3 (en) 1998-06-12 2018-01-08 Icahn School Med Mount Sinai Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and drugs
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
MXPA01010320A (es) 1999-04-13 2003-09-15 Us Health Produccion de vacunas con virus sincitial respiratorio quimerico atenuado a partir de secuencias nucleotidas clonadas.
CN101392239A (zh) 1999-07-09 2009-03-25 美国政府健康及人类服务部 减毒的人-牛嵌合副流感病毒(piv)疫苗
CN101260386A (zh) 1999-07-09 2008-09-10 美国政府健康及人类服务部 减毒的人-牛嵌合呼吸道合胞病毒疫苗的生产
US7820182B2 (en) 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
CN102766605A (zh) * 1999-12-10 2012-11-07 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
DK1292615T3 (da) 2000-06-23 2007-02-19 Wyeth Corp Modificerede morbillivirus V-proteiner
AU2001271909A1 (en) * 2000-07-05 2002-01-14 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
KR101105984B1 (ko) 2001-01-19 2012-01-18 비로노바티브 비.브이. 감응성 포유류에서 호흡계 질환을 유발하는 바이러스
ATE509097T1 (de) * 2001-11-21 2011-05-15 Us Health Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
CA2743750A1 (en) 2002-02-21 2003-09-04 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from respiratory syncytial virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
CN1678345A (zh) 2002-04-26 2005-10-05 米迪缪尼疫苗股份有限公司 制备流感病毒的多质粒系统
EP1572947B1 (de) * 2002-09-18 2014-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services GEWINNUNG VON REKOMBINANTEM HUMANEM PARAINFLUENZA-VIRUS TYP 2 (HPIV2) AUS cDNA UND VERWENDUNG VON REKOMBINANTEM HPIV2 IN IMMUNOGENEN ZUSAMMENSETZUNGEN SOWIE ALS VEKTOREN ZUR HERVORRUFUNG VON IMMUNREAKTIONEN GEGEN PIV UND ANDERE MENSCHLICHE KRANKHEITSERREGER
AU2004262624B2 (en) 2003-02-28 2009-11-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant human metapneumovirus and its use
EP1623006A4 (de) 2003-04-25 2009-10-28 Medimmune Vaccines Inc Metapneumovirus-stämme und ihre verwendung in impfstofformulierungen und als vektoren zur expression antigener sequenzen sowie verfahren zur viruspropagierung
AU2004249133B2 (en) 2003-05-28 2009-05-28 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
KR101020532B1 (ko) 2003-06-09 2011-03-09 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의 회수를 위한 개선된 방법
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
EP1766059B1 (de) 2004-05-25 2012-07-11 MedImmune Vaccines, Inc. Influenza-hämagglutinin- und neuraminidase-varianten
US8124101B2 (en) 2004-06-01 2012-02-28 Mount Sinai School Of Medicine Genetically engineered swine influenza virus and uses thereof
EP1814990A2 (de) 2004-11-19 2007-08-08 Wisconsin Alumni Research Foundation Rekombinante influenza-vektoren mit transkriptionseinheiten, die in tandem vorliegen
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP2251034B1 (de) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimäre newcastle disease viren zur präsentation von nicht -nativen oberflächenproteinen und deren verwendung
JP4905649B2 (ja) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 魚用ワクチン、その製造方法、および魚類感染症の予防方法
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン，エルエルシー イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
AU2007286161B2 (en) 2006-08-09 2013-05-02 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2069484B1 (de) 2007-06-18 2014-08-13 MedImmune, LLC Influenza-B-Viruses mit verändertem Hämagglutininpolypeptid
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
US8591914B2 (en) 2008-07-11 2013-11-26 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ES2550179T3 (es) 2009-02-05 2015-11-05 Icahn School Of Medicine At Mount Sinai Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
SG2014010185A (en) 2009-02-12 2014-06-27 Medimmune Llc Influenza hemagglutinin and neuraminidase variants
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
US9217157B2 (en) 2009-07-27 2015-12-22 Icahn School Of Medicine At Mount Sinai Recombinant influenza viruses and uses thereof
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CN103068835A (zh) * 2010-06-06 2013-04-24 西奈山医学院 重组rna 病毒及其用途
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
HRP20230694T1 (hr) 2013-02-08 2023-10-13 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Smanjenje ljudskog respiratornog sincicijskog virusa prema ljestvici genoma deoptimizacijom kodon-para
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2014241843B2 (en) 2013-03-14 2019-05-02 Icahn School Of Medicine At Mount Sinai Newcastle disease viruses and uses thereof
AU2014290203B2 (en) 2013-07-15 2020-12-24 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
CN107073099B (zh) 2014-02-27 2022-09-27 默沙东公司 用于治疗癌症的联合方法
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
WO2016118642A1 (en) * 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant human/bovine parainfluenza virus 3 (b/hpiv3) expressing a chimeric rsv/bpiv3 f protein and uses thereof
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
BR112017015789A2 (pt) 2015-02-26 2018-03-27 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus da influenza suína bivalente
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
AU2016308917A1 (en) 2015-08-20 2018-03-15 Cornell University Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
WO2017031401A2 (en) 2015-08-20 2017-02-23 University Of Rochester Ns1 truncated virus for the development of canine influenza vaccines
AU2017221444B2 (en) 2016-02-19 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Improved influenza B virus replication for vaccine development
MX388635B (es) 2016-06-03 2025-03-20 Univ Rochester Vacunas atenuadas vivas del virus de la influenza equina
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
JP7198759B2 (ja) 2016-09-23 2023-01-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ 弱毒化表現型を有するヒト呼吸器多核体ウイルス（ｒｓｖ）のためのワクチン候補
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3630173A1 (de) 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Rekombinantes chimäres bovines/humanes parainfluenzavirus 3, das rsv g exprimiert, und seine verwendung
US11197926B2 (en) 2017-10-25 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
MX2020008927A (es) 2018-02-27 2021-01-08 Univ Rochester Vacuna contra la influenza atenuada viva multivalente para la prevencion y el control del virus de la influenza equina (eiv) en caballos.
EP3810634A4 (de) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaik-influenzavirus-hämagglutinin-polypeptide und deren verwendungen
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
EP3914295A2 (de) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren
CN113874496A (zh) 2019-02-08 2021-12-31 威斯康星校友研究基金会(Warf) 人源化细胞系
EP3930749A1 (de) 2019-02-27 2022-01-05 University of Rochester Multivalenter abgeschwächter influenza-lebendimpfstoff zur vorbeugung und kontrolle des equinen influenzavirus (eiv) bei pferden
EP3959216A4 (de) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP7627911B2 (ja) 2019-08-27 2025-02-07 ウィスコンシン アルムニ リサーチ ファンデイション 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス
CN110628724B (zh) * 2019-09-25 2023-04-14 兰州生物制品研究所有限责任公司 一种三型副流感病毒野毒株及其应用
WO2021150874A1 (en) 2020-01-24 2021-07-29 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized na
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US20230201327A1 (en) 2020-05-13 2023-06-29 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Rsv vaccine bearing one or more p gene mutations
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
TW202529819A (zh) 2023-10-13 2025-08-01 美商旗艦先鋒創新公司 組織特異性指環載體(anellovector)遞送
TW202535439A (zh) 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物
WO2025128971A1 (en) 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated
WO2025160409A1 (en) 2024-01-26 2025-07-31 Flagship Pioneering Innovations V, Inc. Viral vectors for modulating vegf function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7007491A (en) * 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
EP1394259A3 (de) * 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Rekombinantes infektiöses nicht-in-Segmente-geteiltes negativ-Strange-RNS-Virus
BR9610590A (pt) * 1995-09-22 2000-10-24 Connaught Lab Glicoproteìnas e vacinas de vìrus parainfluenza
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine

Also Published As

Publication number Publication date
DE69842165D1 (de) 2011-04-21
JP2008307055A (ja) 2008-12-25
EP0994949A1 (de) 2000-04-26
WO1998053078A1 (en) 1998-11-26
CA2291216A1 (en) 1998-11-26
CN1250725C (zh) 2006-04-12
JP4384244B2 (ja) 2009-12-16
JP2002502241A (ja) 2002-01-22
CN1306575A (zh) 2001-08-01
AU7797798A (en) 1998-12-11
KR20010012893A (ko) 2001-02-26
KR100702523B1 (ko) 2007-04-04
BR9809456B1 (pt) 2011-06-28
EP0994949B1 (de) 2011-03-09
JP4237268B2 (ja) 2009-03-11
BR9809456A (pt) 2000-06-13

Similar Documents

Publication Publication Date Title
ATE501259T1 (de) Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
ATE366314T1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
DE60334310D1 (de) Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
BR0016145A (pt) Clones infecciosos
ATE452210T1 (de) Rekombinante newcastle-disease-virus rna expressionssysteme und impfstoffe
CA2283464A1 (en) Functional dna clone for hepatitis c virus (hcv) and uses thereof
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
CA2230452A1 (en) Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof
DE69332831D1 (de) Rekombinanter schweinepocken-virus
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
CA2430115A1 (en) Recombinant rsv virus expression systems and vaccines
BR0015740A (pt) Mutações de faixa de hospedeiro de vìrus de membrana e seus usos como substratos de vacinas
WO2000012677A3 (en) Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
WO1996001615A3 (en) Hepatitis a virus deletion mutants and vaccine formulations containing the same
DE69814884D1 (de) Hepatitis b virale polypeptide
MY206950A (en) A 2-in-1 universal influenza a vaccine based on recombinant virus-like particles
WO2001011065A3 (en) Hepatitis a virus clones adapted for growth in agmk cells
Zuckerman et al. Direct sequence determination of the influenza B HA-1 gene after PCR amplification of clinical specimens from an infected volunteer
Andzhdaparidze et al. Chronic rubella virus-induced infection of human continuous cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties